<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2340-9894</journal-id>
<journal-title><![CDATA[Ars Pharmaceutica (Internet)]]></journal-title>
<abbrev-journal-title><![CDATA[Ars Pharm]]></abbrev-journal-title>
<issn>2340-9894</issn>
<publisher>
<publisher-name><![CDATA[Universidad de Granada]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2340-98942021000300224</article-id>
<article-id pub-id-type="doi">10.30827/ars.v62i3.15493</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Preparation and characterization of topical solid lipid nanoparticles containing deferoxamine]]></article-title>
<article-title xml:lang="es"><![CDATA[Preparación y caracterización de nanopartículas lipídicas sólidas tópicas que contienen deferoxamina]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Makhmalzade]]></surname>
<given-names><![CDATA[Behzad Sharif]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Karami]]></surname>
<given-names><![CDATA[Masoud Ali]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rad]]></surname>
<given-names><![CDATA[Narges Mosaddegh]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Ahvaz Jundishapur University of Medical Sciences Health Research Institute Nanotechnology Research Center]]></institution>
<addr-line><![CDATA[Ahvaz ]]></addr-line>
<country>Iran</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>09</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>09</month>
<year>2021</year>
</pub-date>
<volume>62</volume>
<numero>3</numero>
<fpage>224</fpage>
<lpage>234</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S2340-98942021000300224&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S2340-98942021000300224&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S2340-98942021000300224&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction:  Deferoxamine mesylate increases hypoxia inducible factor-1 alpha transactivation by preventing iron-catalyzed reactive oxygen stress, so it can be used to improve diabetic ulcer healing. This study was undertaken to develop and study physicochemical properties of topical deferoxamine-loaded solid lipid nanoparticles.  Method:  Solid lipid nanoparticles were prepared using cold homogenization technique and full factorial design to evaluate the effect of surfactant type and amount of lipid. In-vitro characterization of formulations including particle size and distribution, thermal behavior using Differential Scanning Calorimetry, entrapment efficiency, and release profile were carried out.  Results:  The results showed an acceptable range of particle size (2.88-174 nm), a narrow size distribution, and an average of 60% for drug entrapment efficiency which is significant for a hydrophilic drug. The results from release study showed an initial burst release followed by a slow and prolonged manner. Differential Scanning Calorimetry results also confirmed the results obtained from loading and release evaluations. The best formulation which had a high level of drug loading and the lowest drug release rate contained compritol and oleic acid in the amount of 8% of the total formula, as well as tween 80 and lecithin as a mixture of surfactants.  Conclusions:  The study demonstrated deferoxamine could be loaded in solid lipid nanoparticles to deliver topically.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción:  El mesilato de deferoxamina aumenta la transactivación alfa inducible por hipoxia del factor 1 al prevenir el estrés por oxígeno reactivo catalizado por hierro, por lo que puede usarse para mejorar la cicatrización de la úlcera diabética. Este estudio se llevó a cabo para desarrollar y estudiar las propiedades fisicoquímicas de nanopartículas lipídicas sólidas cargadas con deferoxamina tópica.  Método:  Se prepararon nanopartículas de lípidos sólidos utilizando la técnica de homogeneización en frío y un diseño factorial completo para evaluar el efecto del tipo de tensioactivo y la cantidad de lípidos. Se llevó a cabo la caracterización in vitro de las formulaciones, incluido el tamaño y la distribución de las partículas, el comportamiento térmico mediante calorimetría de barrido diferencial, la eficiencia de atrapamiento y el perfil de liberación.  Resultados:  Los resultados mostraron un rango aceptable de tamaño de partícula (2,88-174 nm), una distribución de tamaño estrecha y un promedio del 60% para la eficacia de atrapamiento del fármaco, lo que es significativo para un fármaco hidrófilo. Los resultados del estudio de liberación mostraron una liberación de ráfaga inicial seguida de una manera lenta y prolongada. Los resultados de la calorimetría diferencial de barrido también confirmaron los resultados obtenidos de las evaluaciones de carga y liberación. La mejor formulación que tenía un alto nivel de carga de fármaco y la menor tasa de liberación de fármaco contenía compritol y ácido oleico en una cantidad del 8% de la fórmula total, así como tween 80 y lecitina como una mezcla de tensioactivos.  Conclusiones:  El estudio demostró que el mesilato de deferoxamina podría cargarse en nanopartículas de lípidos sólidos para administrar por vía tópica.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Mesilato de deferoxamina]]></kwd>
<kwd lng="es"><![CDATA[Nanopartículas de lípidos sólidos]]></kwd>
<kwd lng="es"><![CDATA[Entrega de formulación tópica]]></kwd>
<kwd lng="en"><![CDATA[Deferoxamine mesylate]]></kwd>
<kwd lng="en"><![CDATA[Solid Lipid Nanoparticles]]></kwd>
<kwd lng="en"><![CDATA[Topical formulation deliver]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yih-Kuen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Shen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Foreman]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
<name>
<surname><![CDATA[Ennis]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Skin blood flow response to locally applied mechanical and thermal stresses in the diabetic foot]]></article-title>
<source><![CDATA[Microvasc Res]]></source>
<year>2013</year>
<volume>89</volume>
<page-range>40-6</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dominik]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Evgenios]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Wong]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Maan]]></surname>
<given-names><![CDATA[ZN]]></given-names>
</name>
<name>
<surname><![CDATA[Rennert]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
<name>
<surname><![CDATA[Inayathullah]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Transdermal deferoxamine prevents pressure-induced diabetic ulcers]]></article-title>
<source><![CDATA[PNAS 6]]></source>
<year>2015</year>
<volume>112</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>94-9</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="">
<source><![CDATA[Iranian National Formulary]]></source>
<year>2005</year>
<edition>4th Edition</edition>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hom]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Goding]]></surname>
<given-names><![CDATA[GS]]></given-names>
</name>
<name>
<surname><![CDATA[Price]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Pernell]]></surname>
<given-names><![CDATA[KJ]]></given-names>
</name>
<name>
<surname><![CDATA[Maisel]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The effects of conjugated deferoxamine in porcine skin flap]]></article-title>
<source><![CDATA[Head Neck]]></source>
<year>2000</year>
<volume>22</volume>
<page-range>579-84</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dragsten]]></surname>
<given-names><![CDATA[PR]]></given-names>
</name>
<name>
<surname><![CDATA[Hallaway]]></surname>
<given-names><![CDATA[PE]]></given-names>
</name>
<name>
<surname><![CDATA[Hanson]]></surname>
<given-names><![CDATA[GJ]]></given-names>
</name>
<name>
<surname><![CDATA[Berger]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
<name>
<surname><![CDATA[Bernard]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Hedlund]]></surname>
<given-names><![CDATA[BE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[First human studies with a high-molecular-weight iron chelator]]></article-title>
<source><![CDATA[J Lab Clin Med]]></source>
<year>2000</year>
<page-range>57-65</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lazaridou]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Christodoulou]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Nerantzaki]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kostoglou]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lambropoulou]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Katsarou]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Formulation and In-Vitro Characterization of Chitosan-Nanoparticles Loaded with the Iron Chelator Deferoxamine Mesylate (DFO)]]></article-title>
<source><![CDATA[Pharmaceutics]]></source>
<year>2020</year>
<volume>12</volume>
<page-range>238</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hejazi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Safari]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Arjmand]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Qorbani]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Pourrostami]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Safari]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of Combined versus Monotherapy with Deferoxamine and Deferiprone in Iron Overloaded Thalassemia Patients: a Randomized Clinical Trial]]></article-title>
<source><![CDATA[Int J Pediatr]]></source>
<year>2016</year>
<volume>4</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1959-65</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thanh]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Tecilazich]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Kafanas]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Doupis]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Gnardellis]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Leal]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mechanisms Involved in the Development and Healing of Diabetic Foot Ulceration]]></article-title>
<source><![CDATA[Diabetes]]></source>
<year>2012</year>
<volume>61</volume>
<page-range>2937-47</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Clayton]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Tom]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
</person-group>
<source><![CDATA[A review of the pathophysiology, classification, and treatment of foot ulcers in diabetic patients]]></source>
<year>2009</year>
<publisher-name><![CDATA[American Diabetes Association (R) Inc]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Küchler]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Radowski Michal]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Blaschke]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Dathe]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Plendl]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Haag]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nanoparticles for skin penetration enhancement - A comparison of a dendritic core-multishell-nanotransporter and solid lipid nanoparticles]]></article-title>
<source><![CDATA[Eur J Pharm Biopharm]]></source>
<year>2009</year>
<volume>71</volume>
<page-range>243-50</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mehnert]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Mader]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Solid lipid nanoparticles Production, characterization and applications]]></article-title>
<source><![CDATA[Ad Drug Del Rev]]></source>
<year>2012</year>
<volume>47</volume>
<page-range>165-96</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rainer]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mu¨ller, Ma¨der K, Gohla S Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art]]></article-title>
<source><![CDATA[Eur J Pharm Biopharm]]></source>
<year>2000</year>
<numero>50</numero>
<issue>50</issue>
<page-range>161-77</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jee]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Lim]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Jeong-Sook]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Chong-Kook]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Stabilization of all-trans retinol by loading lipophilic antioxidants in solid lipid nanoparticles]]></article-title>
<source><![CDATA[Eur J Pharm Biopharm]]></source>
<year>2006</year>
<volume>63</volume>
<page-range>134-9</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wissing]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Kayser]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Müller]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Solid lipid nanoparticles for parenteral drug delivery]]></article-title>
<source><![CDATA[Adv Drug Deliv Rev]]></source>
<year>2004</year>
<volume>56</volume>
<page-range>1257-72</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wissing]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Müller]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cosmetic applications for solid lipid nanoparticles (SLN)]]></article-title>
<source><![CDATA[Int J Pharm]]></source>
<year>2003</year>
<volume>254</volume>
<page-range>65-8</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Weiss]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Decker]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
<name>
<surname><![CDATA[McClements]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Kristbergsson]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Helgason]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Awad]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Solid Lipid Nanoparticles as Delivery Systems for Bioactive Food Components]]></article-title>
<source><![CDATA[Food Biophysics]]></source>
<year>2008</year>
<volume>3</volume>
<page-range>146-54</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Coppert]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
<name>
<surname><![CDATA[Muller]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adsorption kinetics of plasma proteins on solid lipid nanoparticles for drug targeting]]></article-title>
<source><![CDATA[Int J Pharm]]></source>
<year>2005</year>
<volume>302</volume>
<page-range>172-86</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ramteke]]></surname>
<given-names><![CDATA[KH]]></given-names>
</name>
<name>
<surname><![CDATA[Joshi]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Dhole]]></surname>
<given-names><![CDATA[SN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Solid Lipid Nanoparticle: A Review]]></article-title>
<source><![CDATA[IOSR J Pharmacy]]></source>
<year>2012</year>
<volume>2</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>34-44</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[El-Gizawya]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Nouhb]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Saberc]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kira]]></surname>
<given-names><![CDATA[AY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Deferoxamine-loaded transfersomes accelerates healing of pressure ulcers in streptozotocin-induced diabetic rats]]></article-title>
<source><![CDATA[JDDST]]></source>
<year>2020</year>
<volume>58</volume>
<page-range>101732</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Si-Qian]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Ch]]></surname>
<given-names><![CDATA[Chen]]></given-names>
</name>
<name>
<surname><![CDATA[Jun-Jun]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Ying]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Xiao-Qian]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Zh]]></surname>
<given-names><![CDATA[Dan-Ping]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Co-delivery of deferoxamine and hydroxysafflor yellow A to accelerate diabetic wound healing via enhanced angiogénesis]]></article-title>
<source><![CDATA[Drug Deliv]]></source>
<year>2018</year>
<volume>25</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1779-89</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Muller-Goymann]]></surname>
<given-names><![CDATA[CC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Physicochemical characterization of colloidal drug delivery systems such as reverse micelles, vesicles, liquid crystals and nanoparticles for topical administration]]></article-title>
<source><![CDATA[Eur J Pharm Biopharm]]></source>
<year>2004</year>
<volume>58</volume>
<page-range>343-56</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mukherjee]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ray]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Thakur]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Solid Lipid Nanoparticles: A Modern Formulation Approach in Drug Delivery System]]></article-title>
<source><![CDATA[Indian J Pharm Sci]]></source>
<year>2009</year>
<volume>71</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>349-58</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fanga]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
<name>
<surname><![CDATA[Al-Suwayehb]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Fang]]></surname>
<given-names><![CDATA[JY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nanostructured Lipid Carriers (NLCs) for Drug Delivery and Targeting]]></article-title>
<source><![CDATA[Recent Pat Nanotechnol]]></source>
<year>2013</year>
<volume>7</volume>
<page-range>41-55</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
